---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241705"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:54.428386+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M

## Summary
- CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.
- Board member Jan Reed appointed Lead Independent Director; search for permanent CEO commenced.
- Preliminary Q3 2025 revenue expected ~$17M; company to provide update on Nov 6 earnings call.
- OrbiMed waived Q3 2025 trailing 12-month net revenue covenant; discussions underway to redefine future covenants.
- Departure not due to any disagreement with the company on operations, policies, or practices.

## SEC filing metadata
- accession: 0001193125-25-241705
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312525241705/0001193125-25-241705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312525241705/rcel-20251016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241705
- JSON: https://secwatch.observer/filing/0001193125-25-241705.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.